XML 66 R54.htm IDEA: XBRL DOCUMENT v3.22.4
License Agreements - Syros (Details)
$ / shares in Units, $ in Thousands
1 Months Ended 12 Months Ended
Sep. 30, 2022
shares
Jan. 31, 2018
USD ($)
programTarget
Dec. 31, 2022
USD ($)
Dec. 31, 2021
USD ($)
Dec. 31, 2020
USD ($)
$ / shares
Dec. 31, 2018
USD ($)
$ / shares
shares
License agreements            
Purchase price of common stock         $ 150,000  
Per share price (in dollars per share) | $ / shares         $ 41.33  
Unrealized gain (loss) on long term investments     $ (87,590) $ (24,072) $ 10,426  
Syros Pharmaceuticals, Inc.            
License agreements            
Number of program targets | programTarget   7        
Fair value of shares on the issuance date     300 3,100    
Unrealized gain (loss) on long term investments     $ (2,700) $ (7,100) $ 3,700  
Syros Pharmaceuticals, Inc. | Stock purchase agreement            
License agreements            
Purchase of common stock under Stock Purchase Agreement (in shares ) | shares           800,000
Purchase price of common stock           $ 10,000
Per share price (in dollars per share) | $ / shares           $ 12.61
Syros Pharmaceuticals, Inc. | Amended stock purchase agreement            
License agreements            
Purchase of common stock under Stock Purchase Agreement (in shares ) | shares           100,000
Purchase price of common stock           $ 1,400
Per share price (in dollars per share) | $ / shares           $ 9.55
Syros Pharmaceuticals, Inc. | Maximum            
License agreements            
Target selection and option exercise fee payment   $ 54,000        
Syros Pharmaceuticals, Inc. | Development and Regulatory Milestones | Maximum            
License agreements            
Additional milestone payments under the license agreement   50,000        
Syros Pharmaceuticals, Inc. | Commercialization Milestones | Maximum            
License agreements            
Additional milestone payments under the license agreement   $ 65,000        
Stock purchase agreement | Syros Pharmaceuticals, Inc.            
License agreements            
Conversion ratio 0.1          
Investment owned (in shares) | shares 93,753